王淼 教授
博士教授 博士生导师
血管生物学与药理学课题组组长
Miao WangPh.D.
Professor
Laboratory of Vascular Biology and Pharmacology
E-mail:wangmiao_frank@aliyun.com
个人简介：
王淼博士1996年毕业于浙江大学生物科学与技术系，1999年于浙江大学获得动物生理生化方向硕士学位，2002年于北京协和医学院获得病毒免疫学方向博士学位。在美国宾夕法尼亚大学(University of Pennsylvania)药理系从事博士后研究，获得美国宾夕法尼亚大学医学院临床研究认证（ 临床流行病学与生物统计学）。2006年起先后担任宾西法尼亚大学药理系做研究助理（Research Associate）和研究助理教授（Research Assistant Professor)。2010起受聘为美国辉瑞制药全球研发(Pfizer Global R&D)心血管与代谢性疾病研发部主要科学家(Principal Scientist)。2013年就职于中国医学科学院/北京协和医学院心血管疾病国家重点实验室和阜外医院临床药理中心。长期从事心血管疾病分子细胞生物学、疾病动物模型与药物发现研究。

Education Background & Professional Experience:
Dr. Wang is a Professor and the Head of Laboratory of Cardiovascular Inflammation and Therapeutic Innovation, State Key Laboratory of Cardiovascular Disease, China. He got a Bachelor degree and a Master degree from Zhejiang University, and obtained a Ph.D. from Peking Union Medical College/Chinese Academy of Medical Sciences in 2002. Dr. Wang completed postdoctoral research and obtained a Clinical Research Certificate in Clinical Epidemiology & Biostatistics, at University of Pennsylvania, and then joined the faculty of the Department of Pharmacology, as Research Associate andResearch Assistant Professor from 2006-2010.
Besides his academic experience, Dr. Wang had been working in the Cardiovascular and Metabolic Disease Research Unit at Pfizer, as Principal Scientist, since 2010 until he took the current position in 2013.
Dr. Wang is a lifelong member of Sino-American Pharmaceutical Professionals Association (SAPA).
研究领域：
运用分子细胞生物学和遗传学手段，结合疾病动物模型研究和临床研究，深入探讨心血管疾病的发病机制，并探讨其可能的治疗应用。
目前研究集中于（1）活性脂类小分子（如前列腺素类分子）在心血管炎症疾病中的病理与药理作用；（2）新药靶的心血管功能鉴定与治疗应用。
Research Interests:
The laboratory aims to elucidate the mechanisms of cardiovascular diseases, particularly those of atherosclerosis and related complications, by integrating molecular, cellular, and genetic approaches with animal model and clinical research, and to translate such novel mechanistic insights into therapeutic innovation. Our current research is focused on (1)the pathological and pharmacological function of bioactive lipids, such as prostanoids, in cardiovascular inflammation; (2) validation and therapeutic exploration of novel cardiovascular drug targets, through worldwide collaboration with academia and pharmaceutical industry.
代表性的SCI论文/Selected Publications:
1)Wang M* (*Corresponding author), Jin W, Guo AM, Stubbe J. Cardiovascular Inflammation.Mediators of Inflammation. 2013 (In press).
2)Knight DR, Smith AH, Schroeder RL, Huang C, Beebe DA, Sokolowski SA,Wang M* (*Corresponding author). Effects of age on noninvasive assessments of vascular function in nonhuman primates: implications for translational drug discovery.Journal of Translational Medicine.2013, 11:101 doi:10.1186/1479-5876-11-101
3)Lowell AN, Qiao H, Liu T, Ishikawa T, Zhang H, Oriana S,Wang M, Ricciotti E, FitzGerald GA, Zhou R, and Yamakoshi Y. Functionalized Low-Density Lipoprotein Nanoparticles for in Vivo Enhancement of Atherosclerosis on Magnetic Resonance Images.Bioconjugate Chem.2012; 23(11):2313-9.
4)Wang M* (*Corresponding author), Ihida-Stansbury K, Kothapalli D, Tamby MC, Yu Z, Chen L, Grant G, Cheng Y, Lawson JA, Assoian RK, Jones PL, Fitzgerald GA*. Microsomal Prostaglandin E₂Synthase-1 Modulates the Response to Vascular Injury.Circulation. 2011;123(6):631-9.
5)Hui Y, Crichton I, Ricciotti E, Yu Z, Wang D, Stubbe J,Wang M, Puré E, FitzGerald GA. Targeted Deletions of COX-2 and Atherogenesis in Mice.Circulation. 2010;121(24):2654-60
6)Wang M* (*Corresponding author), Jiang M, Cooper PR, Zhao H, Hui Y, Yao Y, Tate JC, Damera G, Lawson JA., Jester WF, Panettieri RA and FitzGerald GA. Deletion of microsomal Prostaglandin E Synthase does not alter ozone-induced airway hyper-responsiveness.J Pharmacol Exp Ther. 2010;334(1):63-8
7)Damera G, Zhao H,Wang M, Smith M, Kirby C, Jester WF, Lawson JA, Panettieri RA Jr. Ozone modulates IL-6 secretion in human airway epithelial and smooth muscle cells.Am J Physiol Lung Cell Mol Physiol. 2009;296(4):L674-83.
8)Wang Y, Barthold J, Figueroa E, González R, Noh PH,Wang M, Manson J. Analysis of five single nucleotide polymorphisms in the ESR1 gene in cryptorchidism.Birth Defects Res AClin Mol Teratol. 2008;82(6):482-5
9)Wang M, Lee E, Song W-L, Ricciotti E, Rader DJ, Lawson JA, Puré E and FitzGerald GA.Microsomal PGE Synthase-1 Deletion Suppresses Oxidative Stress and Angiotensin II Induced Abdominal Aortic Aneurysm Formation.Circulation, 2008;117(10):1302-9.
10)Song WL,Wang M, Ricciotti E, Fries S, Yu Y, Grosser T, Reilly M, Lawson JA, FitzGerald GA. Tetranor PGDM: An abundant urinary metabolite reflects biosynthesis of PGD₂in mice and humans.J Biol Chem. 2008;283(2):1179-88.
11)Song WL, Lawson JA,Wang M, Zou H, FitzGerald GA.Noninvasive Assessment of the Role of Cyclooxygenases in Cardiovascular Health: A Detailed HPLC/MS/MS Method.Methods in Enzymol. 2007;433:51-72.
12)Wang M, Zukas AM, Hui Y, Ricciotti E, Puré E and FitzGerald GA. Deletion of microsomal PGE synthase -1 augments prostacyclin and retards atherogenesis.Proc Natl Acad Sci U S A. 2006; 103(39):14507-12.
13)Cheng Y,Wang M(co-first authorship), Yu Y, Lawson JA, Funk CD and FitzGerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function.J Clin Invest. 2006;116(5):1391-9.
14)Wang D,Wang M, Cheng Y, FitzGerald GA.Cardiovascular hazard and non-steroidal anti-inflammatory drugs.Curr Opin Pharmacol. 2005, 5(2):204-10.
15)Egan KM,Wang M, Lucitt MB, Zukas AM, Puré E, Lawson JA and FitzGerald GA. Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism.Circulation, 2005, 111(3): 334-342
16)Wang M, Chen L, Wang L, Han Y, Zou Y, Si J, Song G. Expression of Human Papillomavirus Type 6 L1 and L2 Isolated in China and Self Assembly of Virus-like Particles by the Products.Acta Biochimica et Biophysica Sinica, 2003, 35(1): 27-34